Editorial
Challenges facing regionalization of radical cystectomy
Abstract
Neoadjuvant chemotherapy followed by radical cystoprostatectomy (RC) or anterior exenteration represents the gold standard for management of muscle invasive bladder cancer. Despite clear best practice guidelines (1,2), utilization of RC varies widely across centers and regions nationwide, likely due to the significant morbidity associated with a major extirpative surgery.